A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease

Exclusion Criteria

• •Participation in a study or received an investigational drug within 30 days of the Baseline Visit
• •Any prior or concomitant use of compounds suspected of interfering with protein acetylation
• •Any concomitant use of medications that are known inhibitors of CYP450 enzymes or substrates of CYP1A2 at the time of enrollment
• •Suicide risk, as determined by meeting either of the following criteria: a) a suicide attempt within the past year or suicidal ideation within 60 days of the Screening Visit; b) Significant risk of suicide, as judged by the Investigator
• •Subjects with MMSE \< 24
• •Subjects with presence of clinically significant psychosis and/or confusional states, in the opinion of the Investigator
• •Subjects with clinically significant laboratory or ECG abnormalities at Screening or Baseline
• •Subjects with clinically relevant hematologic, hepatic, cardiac, or renal disease
• •Subjects with a current or past (within the last 12 months) history of epilepsy or seizures
• •A medical history of infection with human immunodeficiency virus, hepatitis C, and/or hepatitis B
• •Subjects with a history of substance abuse within the past 12 months
• •Female subjects who are pregnant or breastfeeding
• •Known allergy to any ingredient in the study drug
• •A history of malignancy of any type within 2 years prior to Screening. A history of surgically-excised nonmelanoma skin cancers is permitted.
• •Any relevant condition, behavior, laboratory value, or concomitant medication which, in the opinion of the Investigator, makes the subject unsuitable for entry into the study